Insulet Slashes US Sales Outlook, Shares Plunge 12%
PODD is trading near its 52-week low of $138.79 (4.1% above the low).
Summary
Insulet cut its full-year revenue growth forecast to 20-22% from 21-23%, driven by a sharper slowdown in U.S. Omnipod sales — now seen growing 17-19% vs. prior 20-22%. The revision confirms fears that competition and a maturing type 2 diabetes ramp are eroding growth faster than expected. Q2 results beat on both top and bottom lines, with revenue of $801.7M and adjusted EPS of $1.66, but the guidance cut overshadows the beat. International guidance was raised to 30-32% growth, partially offsetting U.S. weakness. This follows a May device correction and a July securities fraud lawsuit, adding to a negative narrative. The stock, already near 52-week lows, fell over 12% pre-market, signaling deep investor concern about the growth trajectory into 2027.
At the time of this announcement, PODD was trading at $144.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6B. The 52-week trading range was $138.79 to $354.88. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.